PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions.
Chukwuka EzeNina-Sophie Schmidt-HegemannLino Morris SawickiJulian KirchnerOlarn RoengvoraphojLukas KäsmannLena M MittlmeierWolfgang G KunzAmanda TufmanJulien DinkelJens RickeClaus BelkaFarkhad ManapovMarcus UnterrainerPublished in: European journal of nuclear medicine and molecular imaging (2021)
The advent of ICIs marks the dawn of a new era bringing forth new challenges particularly vis-à-vis treatment response assessment and observation of novel phenomena accompanied by novel systemic side effects. While FDG PET/CT is widely adopted for tumor volume delineation in locally advanced disease, response assessment to immunotherapy based on current criteria is of high clinical value but has its inherent limitations. In recent years, modifications of established (PET)/CT criteria have been proposed to provide more refined approaches towards response evaluation. Not only a comprehensive inclusion of PET-based response criteria in prospective randomized controlled trials, but also a general harmonization within the variety of PET-based response criteria is pertinent to strengthen clinical implementation and widespread use of hybrid imaging for response assessment in NSCLC.
Keyphrases
- pet ct
- positron emission tomography
- small cell lung cancer
- high resolution
- randomized controlled trial
- healthcare
- locally advanced
- primary care
- oxidative stress
- squamous cell carcinoma
- clinical trial
- advanced non small cell lung cancer
- rectal cancer
- quality improvement
- study protocol
- photodynamic therapy
- brain metastases
- smoking cessation